



Press release

Number of shares and votes in Orexo

Uppsala, Sweden – September 30, 2013 - The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants.

Today, the last trading day of the month, there are in total 32,674,441 shares and votes in the company.

For further information, please contact:

Henrik Juuel, EVP and Chief Financial Officer

Tel: +46 (0)722-20 94 77, E-mail: henrik.juuel@orexo.com

About Orexo

Orexo is an emerging specialty pharma company with commercial operations in the United States and R&D in Sweden developing improved treatments using proprietary drug delivery technology and commercial operations in the United States. The company is commercializing its proprietary product, Zubsolv® (buprenorphine and naloxone), for maintenance treatment of opioid dependence, in the United States. Zubsolv is a novel formulation of buprenorphine and naloxone using Orexo's extensive knowledge in sublingual technologies. Orexo has a portfolio of two approved and revenue generating products currently marketed under license in the EU and US. Orexo AB, with its headquarters in Sweden, is listed on NASDAQ-OMX and OTC market in the US (ORXOY). The largest shareholders are Novo A/S and HealthCap.

For information about Orexo please visit www.orexo.com

Orexo AB (publ) discloses the information provided herein pursuant to the Financial Instruments Trading Act and/or the Securities Markets Act. The information was submitted for publication at 4:30 pm CET on September 30, 2013.